Booth H, Bish R, Walters J, Whitehead F, Walters E H
Department of Respiratory Medicine, Alfred Hospital, Victoria, Australia.
Thorax. 1996 Nov;51(11):1100-4. doi: 10.1136/thx.51.11.1100.
Tachyphylaxis to the protection afforded by salmeterol to broncho-constrictor stimuli after regular use has been described in patients with mild asthma not receiving inhaled corticosteroids. The present study was performed to investigate whether airway tachyphylaxis occurs in symptomatic asthmatic subjects receiving inhaled corticosteroids, the group for whom salmeterol is recommended in clinical practice.
Thirty one adult patients with symptomatic chronic asthma who were receiving inhaled corticosteroids were randomised in a double blind manner and on a 2:1 basis to receive salmeterol 50 micrograms (n = 22) or placebo (n = 9) twice daily. Baseline forced expiratory volume in one second (FEV1) was measured during the run-in period, on day 0, and after four and eight weeks of regular treatment (following a 36 hour test drug washout period). Airway responsiveness to methacholine was measured one hour after administration of the test drug on these occasions. Diary cards were kept throughout the study and for a two week follow up period.
Baseline FEV1 was not significantly different between the treatment groups or between visits. There was significant bronchodilatation one hour after salmeterol administration at 0, four, and eight weeks. No significant tachyphylaxis of the bronchodilator action of salmeterol was seen. Protection against methacholine induced bronchoconstriction reduced from 3.3 doubling dilutions after the first dose of salmeterol to two doubling dilutions after four and eight weeks of regular treatment. Symptom scores and "rescue" salbutamol use were significantly reduced during salmeterol treatment and daytime improvements were maintained into the follow up period.
Inhaled corticosteroids did not prevent tachyphylaxis to the protection afforded by salmeterol to methacholine induced bronchoconstriction. The clinical significance, if any, of these findings remains to be defined.
在未接受吸入性糖皮质激素治疗的轻度哮喘患者中,已发现规律使用沙美特罗后,其对支气管收缩刺激的保护作用会出现快速减敏现象。本研究旨在调查在接受吸入性糖皮质激素治疗的有症状哮喘患者(临床实践中推荐使用沙美特罗的人群)中是否会出现气道快速减敏现象。
31名接受吸入性糖皮质激素治疗的有症状慢性哮喘成年患者,以2:1的比例随机双盲分组,分别每日两次接受50微克沙美特罗(n = 22)或安慰剂(n = 9)治疗。在导入期、第0天以及规律治疗4周和8周后(经过36小时的试验药物洗脱期)测量基线一秒用力呼气量(FEV1)。在这些时间点,给药试验药物1小时后测量气道对乙酰甲胆碱的反应性。在整个研究期间以及为期两周的随访期内,患者记录日记卡。
治疗组之间或各访视之间的基线FEV1无显著差异。在第0周、第4周和第8周,沙美特罗给药1小时后有显著的支气管扩张作用。未观察到沙美特罗支气管扩张作用的显著快速减敏现象。对乙酰甲胆碱诱导的支气管收缩的保护作用从首次给予沙美特罗后的3.3倍稀释度降低至规律治疗4周和8周后的2倍稀释度。在沙美特罗治疗期间,症状评分和“急救”沙丁胺醇的使用显著减少,且日间改善情况在随访期内得以维持。
吸入性糖皮质激素未能预防沙美特罗对乙酰甲胆碱诱导的支气管收缩的保护作用出现快速减敏现象。这些发现的临床意义(若有)仍有待确定。